Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498

Bibliography

• Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45
   PubMed Web of Science ®Google Scholar
• Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998;51:191-200
   PubMedGoogle Scholar
• Cichy J, Pure E. The liberation of CD44. J Cell Biol 2003;161:839-43
   PubMed Web of Science ®Google Scholar
• Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. Febs J 2011;278:1429-43
   PubMed Web of Science ®Google Scholar
• Goodfellow PN, Banting G, Wiles MV, et al. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol 1982;12:659-63
   PubMed Web of Science ®Google Scholar
• Mackay CR, Terpe HJ, Stauder R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82
   PubMed Web of Science ®Google Scholar
• Sheikh H, Legg J, Lewis C, et al. Discrete domains within the hyaluronan receptor CD44 regulate membrane localization and cell migration. Cell Adhes Commun 1998;6:149-56
   PubMed Web of Science ®Google Scholar
• Borland G, Ross JA, Guy K. Forms and functions of CD44. Immunology 1998;93:139-48
   PubMed Web of Science ®Google Scholar
• Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12
   PubMed Web of Science ®Google Scholar
• Ehnis T, Dieterich W, Bauer M, et al. A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Exp Cell Res 1996;229:388-97
   PubMedGoogle Scholar
• Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904
   PubMed Web of Science ®Google Scholar
• Skelton TP, Zeng C, Nocks A, Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol 1998;140:431-46
   PubMed Web of Science ®Google Scholar
• Legg JW, Lewis CA, Parsons M, et al. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol 2002;4:399-407
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 1998;3:d637-49
   PubMedGoogle Scholar
• Pure E, Assoian RK. Rheostatic signaling by CD44 and hyaluronan. Cell Signal 2009;21:651-5
   PubMed Web of Science ®Google Scholar
• Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Bishop JM. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991;11:5446-53
   PubMedGoogle Scholar
• Wielenga VJ, van der Voort R, Mulder JW, et al. CD44 splice variants as prognostic markers in colorectal cancer. Scand J Gastroenterol 1998;33:82-7
   PubMedGoogle Scholar
• De Marzo AM, Bradshaw C, Sauvageot J, et al. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998;34:162-8
   PubMed Web of Science ®Google Scholar
• Negi LM, Talegaonkar S, Jaggi M, et al. Role of CD44 in tumour progression and strategies for targeting. J Drug Target 2012;20:561-73
   PubMed Web of Science ®Google Scholar
• Charrad RS, Li Y, Delpech B, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999;5:669-76
   PubMed Web of Science ®Google Scholar
• Charrad RS, Gadhoum Z, Qi J, et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002;99:290-9
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50
   PubMed Web of Science ®Google Scholar
• Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405-18
   PubMed Web of Science ®Google Scholar
• Ramsay AD, Rodriguez-Justo M. Chronic lymphocytic leukaemia-the role of the microenvironment pathogenesis and therapy. Br J Haematol 2013;162:15-24
   PubMed Web of Science ®Google Scholar
• Audrito V, Vaisitti T, Serra S, et al. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett 2013;328:27-35
   PubMed Web of Science ®Google Scholar
• Eistere W, Hilbe W, Stauder R, et al. An aggressive subtype of B-CLL is characterized by strong CD44 expression and lack of CD11c. Br J Haematol 1996;93:661-9
   PubMed Web of Science ®Google Scholar
• Till KJ, Zuzel M, Cawley JC. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 1999;59:4419-26
   PubMed Web of Science ®Google Scholar
• Girbl T, Hinterseer E, Grossinger EM, et al. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer Res 2013;73:561-70
   PubMed Web of Science ®Google Scholar
• Calpe E, Codony C, Baptista MJ, et al. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011;118:4401-10
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Gibellini F, Njuguna N, et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 2011;52:1758-69
   PubMed Web of Science ®Google Scholar
• Fedorchenko O, Stiefelhagen M, Peer-Zada AA, et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 2013;121:4126-36
   PubMed Web of Science ®Google Scholar
• De Rossi G, Marroni P, Paganuzzi M, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 1997;11:134-41
   PubMedGoogle Scholar
• Zarcone D, De Rossi G, Tenca C, et al. Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells. Haematologica 1998;83:1088-98
   PubMed Web of Science ®Google Scholar
• Eisterer W, Bechter O, Soderberg O, et al. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res 2004;28:1043-51
   PubMed Web of Science ®Google Scholar
• Kipps TJ. CD44 monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies. W02013/063498A1; 2013
   Google Scholar
• Zhang S, Wu CC, Fecteau JF, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA 2013;110:6127-32
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
   PubMed Web of Science ®Google Scholar
• Dianzani U, Bragardo M, Tosti A, et al. CD44 signaling through p56lck involves lateral association with CD4 in human CD4+ T cells. Int Immunol 1999;11:1085-92
   PubMedGoogle Scholar
• Taher TE, Smit L, Griffioen AW, et al. Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. J Biol Chem 1996;271:2863-7
   PubMed Web of Science ®Google Scholar
• Buggins AG, Levi A, Gohil S, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011;154:216-22
   PubMed Web of Science ®Google Scholar
• Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008;112:169-78
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Zucchetto A, et al. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol 2010;20:416-23
   PubMedGoogle Scholar
• Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:3584-92
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110:4012-21
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;15;111(12):5446-56
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 2013;88(9):803-16
   PubMed Web of Science ®Google Scholar
• Qian H, Xia L, Ling P, et al. CD44 ligation with A3D8 antibody induces apoptosis in acute myeloid leukemia cells through binding to CD44s and clustering lipid rafts. Cancer Biol Ther 2012;13:1276-83
   PubMed Web of Science ®Google Scholar
• Sansonetti A, Bourcier S, Durand L, et al. CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. Leuk Res 2012;36:358-62
   PubMedGoogle Scholar
• Maquarre E, Artus C, Gadhoum Z, et al. CD44 ligation induces apoptosis via caspase- and serine protease-dependent pathways in acute promyelocytic leukemia cells. Leukemia 2005;19:2296-303
   PubMedGoogle Scholar
• Artus C, Maquarre E, Moubarak RS, et al. CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathway in human erythroleukemia cells. Oncogene 2006;25:5741-51
   PubMedGoogle Scholar
• Song G, Liao X, Zhou L, et al. HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk Res 2004;28:1089-96
   PubMed Web of Science ®Google Scholar
• Bourcier S, Sansonetti A, Durand L, et al. CD44-ligation induces, through ERK1/2 pathway, synthesis of cytokines TNF-alpha and IL-6 required for differentiation of THP-1 monoblastic leukemia cells. Leukemia 2010;24:1372-5
   PubMedGoogle Scholar
• Peer Zada A, Singh SM, Reddy VA, et al. Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 2003;22:2296-308
   PubMedGoogle Scholar
• Gadhoum Z, Delaunay J, Maquarre E, et al. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004;45:1501-10
   PubMed Web of Science ®Google Scholar
• Allouche M, Charrad RS, Bettaieb A, et al. Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells. Blood 2000;96:1187-90
   PubMed Web of Science ®Google Scholar
• Onoda M, Nakaseko C, Yokota A, Saito Y. Ligation of CD44 with low-molecular-weight hyaluronan and a monoclonal antibody leads to inhibition of drug-induced apoptosis in a human myeloid cell line. Hematology (Am Soc Hematol Educ Program) 2009;14:213-19
   Google Scholar
• Ohwada C, Nakaseko C, Koizumi M, et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur J Hematol 2008;80:245-50
   PubMed Web of Science ®Google Scholar
• Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathways triggers chemoresistance via Lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001;61:5275-83
   PubMed Web of Science ®Google Scholar
• Du YR, Chen Y, Gao Y, et al. Effects and mechanisms of anti-CD44 monoclonal antibody AeD8 on proliferation and apoptosis of sphere-phorming cells with stemness from human ovarian cancer. Int J Gynecol Cancer 2013;23:1367-75
   PubMedGoogle Scholar
• Yasuda M, Tanaka Y, Fujii K, Yasumoto K. CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int Immunol 2001;13:1309-19
   PubMedGoogle Scholar
• Marangoni E, Lecomte N, Durand L, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009;100:918-22
   PubMed Web of Science ®Google Scholar
• A Study of RO5429083 in patients with metastatic and/or locally advanced, CD44-expressing, malignant solid tumors. ClinicalTrials.gov: NCT01358903
   Google Scholar
• A study of RO5429083 alone or in combination with cytarabine in patients with acute myelogenous leukemia. ClinicalTrials.gov: NCT01641250
   Google Scholar
• Tijink BM, Buter J, de Bree RA, et al. Phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12:6064-72
   PubMed Web of Science ®Google Scholar
• Riechelmann H, Sauter A, Golze W, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008;44:823-9
   PubMed Web of Science ®Google Scholar